Pub Date : 2023-03-01DOI: 10.21776/ub.jphv.2023.004.01.3
Fahrani Yossa Prachika, S. Kurniawan
Leprosy is a major cause of peripheral neuropathy in developing countries, affecting sensory, motor, and autonomic nerve function. Neuropathy complications can include sensory loss and muscle weakness. Impaired sensory nerve function is often the first symptom encountered in leprosy neuropathy. Early detection and treatment of neuropathy in leprosy are important to prevent disability.
{"title":"LEPROSY NEUROPATHY","authors":"Fahrani Yossa Prachika, S. Kurniawan","doi":"10.21776/ub.jphv.2023.004.01.3","DOIUrl":"https://doi.org/10.21776/ub.jphv.2023.004.01.3","url":null,"abstract":"Leprosy is a major cause of peripheral neuropathy in developing countries, affecting sensory, motor, and autonomic nerve function. Neuropathy complications can include sensory loss and muscle weakness. Impaired sensory nerve function is often the first symptom encountered in leprosy neuropathy. Early detection and treatment of neuropathy in leprosy are important to prevent disability.","PeriodicalId":126692,"journal":{"name":"JPHV (Journal of Pain, Vertigo and Headache)","volume":"362 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121645483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.21776/ub.jphv.2023.004.01.1
Irsyah Dwi Rohmayanti, S. Kurniawan
Postherpetic neuralgia (PHN) is a chronic neuropathic pain condition that lasts 3 months or more after an outbreak of shingles. Herpes zoster, especially acute herpes zoster, is associated with the reactivation of the inactivated varicella zoster virus in individuals who have had chickenpox. PHN is associated with persistent and often refractory neuropathic pain. Patients may experience several types of pain, including deep pain, intolerable pain, burning, paroxysmal pain, stabbing pain, hyperalgesia, and allodynia. Pharmacological treatment of PHN may include a variety of drugs, including alpha-2 delta ligands (gabapentin and pregabalin), other anticonvulsants (carbamazepine), tricyclic antidepressants (amitriptyline, nortriptyline, doxepin), topical analgesics (5% lidocaine patch, capsaicin) tramadol, or other opioids. The sizeable side effect profile of commonly used oral drugs often limits their practical use, and a combination of topical and systemic agents may be required for optimal results. Doctors and other care providers must adapt treatment based on individual patient responses.
{"title":"POST HERPETIC NEURALGIA","authors":"Irsyah Dwi Rohmayanti, S. Kurniawan","doi":"10.21776/ub.jphv.2023.004.01.1","DOIUrl":"https://doi.org/10.21776/ub.jphv.2023.004.01.1","url":null,"abstract":"Postherpetic neuralgia (PHN) is a chronic neuropathic pain condition that lasts 3 months or more after an outbreak of shingles. Herpes zoster, especially acute herpes zoster, is associated with the reactivation of the inactivated varicella zoster virus in individuals who have had chickenpox. PHN is associated with persistent and often refractory neuropathic pain. Patients may experience several types of pain, including deep pain, intolerable pain, burning, paroxysmal pain, stabbing pain, hyperalgesia, and allodynia. Pharmacological treatment of PHN may include a variety of drugs, including alpha-2 delta ligands (gabapentin and pregabalin), other anticonvulsants (carbamazepine), tricyclic antidepressants (amitriptyline, nortriptyline, doxepin), topical analgesics (5% lidocaine patch, capsaicin) tramadol, or other opioids. The sizeable side effect profile of commonly used oral drugs often limits their practical use, and a combination of topical and systemic agents may be required for optimal results. Doctors and other care providers must adapt treatment based on individual patient responses.","PeriodicalId":126692,"journal":{"name":"JPHV (Journal of Pain, Vertigo and Headache)","volume":"282 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131734012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.21776/ub.jphv.2022.004.01.4
Dewi Permata Sari, S. Kurniawan
Myasthenia gravis is an autoimmune disease of the postsynaptic membrane, especially acetylcholine receptors in the neuromuscular link of skeletal muscle. Patients with myasthenia gravis have a high number globally. The disease occurs due to a disorder that impairs the impulse connection between chemicals traveling from nerve endings and receptors. Clinical symptoms include weakness of the eye muscles (ptosis and diplopia), difficulty swallowing, and difficulty speaking. The diagnosis of myasthenia gravis is based on the patient's complaints obtained in the history, physical and neurological examination, and supporting examinations. The management that can be given is intravenous immunoglobulin (IVIg) therapy, plasma exchange (PE), corticosteroids given together with IVIg and PE, or acetylcholinesterase inhibitors. These treatments can determine the patient's prognosis. If the patient with myasthenia gravis is left to involve the respiratory muscles, then the patient's prognosis becomes worse. In addition, myasthenic crisis and cholinergic crisis may occur, which is a medical emergency.
{"title":"MYASTHENIA GRAVIS","authors":"Dewi Permata Sari, S. Kurniawan","doi":"10.21776/ub.jphv.2022.004.01.4","DOIUrl":"https://doi.org/10.21776/ub.jphv.2022.004.01.4","url":null,"abstract":"Myasthenia gravis is an autoimmune disease of the postsynaptic membrane, especially acetylcholine receptors in the neuromuscular link of skeletal muscle. Patients with myasthenia gravis have a high number globally. The disease occurs due to a disorder that impairs the impulse connection between chemicals traveling from nerve endings and receptors. Clinical symptoms include weakness of the eye muscles (ptosis and diplopia), difficulty swallowing, and difficulty speaking. The diagnosis of myasthenia gravis is based on the patient's complaints obtained in the history, physical and neurological examination, and supporting examinations. The management that can be given is intravenous immunoglobulin (IVIg) therapy, plasma exchange (PE), corticosteroids given together with IVIg and PE, or acetylcholinesterase inhibitors. These treatments can determine the patient's prognosis. If the patient with myasthenia gravis is left to involve the respiratory muscles, then the patient's prognosis becomes worse. In addition, myasthenic crisis and cholinergic crisis may occur, which is a medical emergency.","PeriodicalId":126692,"journal":{"name":"JPHV (Journal of Pain, Vertigo and Headache)","volume":"96 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122877971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.21776/ub.jphv.2023.004.01.2
Mega Yulia Rusmayanti, S. Kurniawan
Lumbar herniated nucleus pulposus (HNP) is a disorder characterized by local displacement of the disc beyond the anatomical boundaries of the intervertebral space causing pain, weakness or numbness, and/or tingling in myotomal or dermatomal distribution. HNP is the most common cause of low back pain. Lumbar HNP itself has several underlying etiologies, such as old age, excessive axial load, connective tissue disorders, and congenital abnormalities. Management of HNP can be carried out non-operatively or operatively, depending on the severity, the symptoms that arise, and the response to non-operative treatment.
{"title":"HNP LUMBALIS","authors":"Mega Yulia Rusmayanti, S. Kurniawan","doi":"10.21776/ub.jphv.2023.004.01.2","DOIUrl":"https://doi.org/10.21776/ub.jphv.2023.004.01.2","url":null,"abstract":"Lumbar herniated nucleus pulposus (HNP) is a disorder characterized by local displacement of the disc beyond the anatomical boundaries of the intervertebral space causing pain, weakness or numbness, and/or tingling in myotomal or dermatomal distribution. HNP is the most common cause of low back pain. Lumbar HNP itself has several underlying etiologies, such as old age, excessive axial load, connective tissue disorders, and congenital abnormalities. Management of HNP can be carried out non-operatively or operatively, depending on the severity, the symptoms that arise, and the response to non-operative treatment.","PeriodicalId":126692,"journal":{"name":"JPHV (Journal of Pain, Vertigo and Headache)","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134087324","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01DOI: 10.21776/ub.jphv.2022.004.01.5
Wa Ode Intan Nur Octina, S. Kurniawan
Cluster headache (CH) is a rare and very painful primary headache syndrome, with an estimated population prevalence of 0.12%. This condition can be episodic (ECH), lasting from 7 days to a year. A consensus statement from the European Headache Federation defines refractory CCH as a CCH with at least three severe attacks per week, even though at least three consecutive trials of adequate preventive care have been tested and managed with both acute and preventive treatment. Inhaled oxygen and subcutaneous sumatriptan are the two most effective acute treatment options for people with CH. Several preventive medications are also available, and the most effective is verapamil. However, most of these agents are not supported by strong clinical evidence. In some patients, this option may be ineffective, particularly in those with chronic CH. Surgical procedures for chronic refractory forms of disorder should then be considered.
{"title":"PATHOPHYSIOLOGY IN CLUSTER HEADACHE: AN UPDATE","authors":"Wa Ode Intan Nur Octina, S. Kurniawan","doi":"10.21776/ub.jphv.2022.004.01.5","DOIUrl":"https://doi.org/10.21776/ub.jphv.2022.004.01.5","url":null,"abstract":"Cluster headache (CH) is a rare and very painful primary headache syndrome, with an estimated population prevalence of 0.12%. This condition can be episodic (ECH), lasting from 7 days to a year. A consensus statement from the European Headache Federation defines refractory CCH as a CCH with at least three severe attacks per week, even though at least three consecutive trials of adequate preventive care have been tested and managed with both acute and preventive treatment. Inhaled oxygen and subcutaneous sumatriptan are the two most effective acute treatment options for people with CH. Several preventive medications are also available, and the most effective is verapamil. However, most of these agents are not supported by strong clinical evidence. In some patients, this option may be ineffective, particularly in those with chronic CH. Surgical procedures for chronic refractory forms of disorder should then be considered.","PeriodicalId":126692,"journal":{"name":"JPHV (Journal of Pain, Vertigo and Headache)","volume":"112 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117270716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-01DOI: 10.21776/ub.jphv.2022.003.02.1
Michelle Anisa, Shahdevi Nandar Kurniawan
Cluster headache (CH) is a trigeminal autonomic cephalgia characterized by attacks of severe unilateral headache accompanied by ipsilateral autonomic symptoms. The prevalence of cluster headache in the overall population is 1 in every 1000 people. The exact etiology of cluster headache remains unclear. However, it is thought that there is a connection between the trigeminovascular system, parasympathetic nerve fibers involved in trigeminal autonomic reflexes, and the hypothalamus. Treatment of CH has three stages, namely: abortive, transitional, and preventive. Cluster headaches tend to subside with age with less frequent attacks and longer periods of remission between attacks.
{"title":"CLUSTER HEADACHE","authors":"Michelle Anisa, Shahdevi Nandar Kurniawan","doi":"10.21776/ub.jphv.2022.003.02.1","DOIUrl":"https://doi.org/10.21776/ub.jphv.2022.003.02.1","url":null,"abstract":"Cluster headache (CH) is a trigeminal autonomic cephalgia characterized by attacks of severe unilateral headache accompanied by ipsilateral autonomic symptoms. The prevalence of cluster headache in the overall population is 1 in every 1000 people. The exact etiology of cluster headache remains unclear. However, it is thought that there is a connection between the trigeminovascular system, parasympathetic nerve fibers involved in trigeminal autonomic reflexes, and the hypothalamus. Treatment of CH has three stages, namely: abortive, transitional, and preventive. Cluster headaches tend to subside with age with less frequent attacks and longer periods of remission between attacks.","PeriodicalId":126692,"journal":{"name":"JPHV (Journal of Pain, Vertigo and Headache)","volume":"53 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116706545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-01DOI: 10.21776/ub.jphv.2022.003.02.3
Auliya Nur Muthmainnina, S. Kurniawan
Tension Type Headache (TTH) is the most common type of headache in all age groups worldwide. Because of its high prevalence and possible association with medical and psychiatric comorbidities, TTH has a large socioeconomic impact. TTH is the type of headache that most patients suffer from, ranging from mild to severe pain that reduces their ability to carry out daily activities. TTH can be classified into an episodic tension-type headache (ETTH) and chronic tension-type headache (CTTH). The lifetime prevalence of TTH is high (78%). Approximately 24% to 37% experience TTH several times a month, 10% experience weekly and 2% to 3% of the population have chronic TTH disease. TTH treatment is carried out with pharmacological and non-pharmacological approaches
{"title":"TENSION TYPE HEADACHE (TTH)","authors":"Auliya Nur Muthmainnina, S. Kurniawan","doi":"10.21776/ub.jphv.2022.003.02.3","DOIUrl":"https://doi.org/10.21776/ub.jphv.2022.003.02.3","url":null,"abstract":"Tension Type Headache (TTH) is the most common type of headache in all age groups worldwide. Because of its high prevalence and possible association with medical and psychiatric comorbidities, TTH has a large socioeconomic impact. TTH is the type of headache that most patients suffer from, ranging from mild to severe pain that reduces their ability to carry out daily activities. TTH can be classified into an episodic tension-type headache (ETTH) and chronic tension-type headache (CTTH). The lifetime prevalence of TTH is high (78%). Approximately 24% to 37% experience TTH several times a month, 10% experience weekly and 2% to 3% of the population have chronic TTH disease. TTH treatment is carried out with pharmacological and non-pharmacological approaches","PeriodicalId":126692,"journal":{"name":"JPHV (Journal of Pain, Vertigo and Headache)","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130609651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Carpal Tunnel Syndrome (CTS) is a symptomatic compression neuropathy of the median nerve characterized by increased pressure in the carpal tunnel and decreased nerve function due to compression of the median nerve in the carpal tunnel. The purpose of the hydrodissection injection method in CTS is to separate the soft tissue adhesions that cause nerve compression and this method are known for being minimally invasive, fast healing, and easy to apply. Local injection of triamcinolone acetonide (TCA) is often used as therapy for CTS because it stabilizes the sodium channels and reduces abnormal stimulatio, thus it relieved the pain. 5% dextrose injection (D5W) is also widely used as therapy of CTS because it is harmless to nerves and may reduce neurogenic inflammation through inhibition of capsaicin-sensitive receptors. Aim: To compare the effectivity of hydrodissection injection therapy using ultrasound guidance with triamcinolone acetonide and 5% dextrose in CTS. Methods: This study recruited 30 participants who diagnosed with CTS and met the inclusion criteria. Participants were divided into two treatment groups, the first group (n=15) was given 1ml TCA injection and 1 ml lidocaine 2%, while the second group (n=15) was given 5% 5 ml Dextrose injection. The parameters measured in this study were NRS, FSS, and SSS value before injection and 4 weeks after injection of the agent. We compared these parameters at week four after injection between the TCA group and the D5W group. Results: NRS values before and 4 weeks after TCA injection (sig 0.001; p <0.05), FSS values (sig 0.020; p <0.05), and SSS values (sig 0.001; p <0.05). NRS before and 4 weeks after injection of D5W (sig 0.002; p <0.05), FSS (sig 0.001; p <0.05), and SSS (sig 0.000; p <0.05). Comparison between TCA injection and D5W injection at 4 weeks after the injection showed that the results was significantly different on NRS (sig 0.806; p> 0.05) for FSS (sig 0.512; p> 0.05) and SSS (sig 0.293; p> 0.05). Conclusion: There is a significant difference in NRS, FSS and SSS values at 4 weeks after hydrodissection injection, using either TCA or D5W. TCA hydrodissection injection compared to D5W hydrodissection injection was equally effective in improving NRS, FSS and SSS after 4 weeks of injection.
{"title":"COMPARISON OF HYDRODISSECTION INJECTION THERAPY USING ULTRASONOGRAPHIC AS GUIDES BETWEEN TRIAMCINOLONE ACETONIDE AND 5% DEXTROSE IN CARPAL TUNNEL SYNDROME","authors":"Widodo Mardi Santoso, Ika Sedar Wasis Sasono, Catur Ari Setianto, Nuretha Hevy","doi":"10.21776/ub.jphv.2022.003.02.5","DOIUrl":"https://doi.org/10.21776/ub.jphv.2022.003.02.5","url":null,"abstract":"Background: Carpal Tunnel Syndrome (CTS) is a symptomatic compression neuropathy of the median nerve characterized by increased pressure in the carpal tunnel and decreased nerve function due to compression of the median nerve in the carpal tunnel. The purpose of the hydrodissection injection method in CTS is to separate the soft tissue adhesions that cause nerve compression and this method are known for being minimally invasive, fast healing, and easy to apply. Local injection of triamcinolone acetonide (TCA) is often used as therapy for CTS because it stabilizes the sodium channels and reduces abnormal stimulatio, thus it relieved the pain. 5% dextrose injection (D5W) is also widely used as therapy of CTS because it is harmless to nerves and may reduce neurogenic inflammation through inhibition of capsaicin-sensitive receptors. Aim: To compare the effectivity of hydrodissection injection therapy using ultrasound guidance with triamcinolone acetonide and 5% dextrose in CTS. Methods: This study recruited 30 participants who diagnosed with CTS and met the inclusion criteria. Participants were divided into two treatment groups, the first group (n=15) was given 1ml TCA injection and 1 ml lidocaine 2%, while the second group (n=15) was given 5% 5 ml Dextrose injection. The parameters measured in this study were NRS, FSS, and SSS value before injection and 4 weeks after injection of the agent. We compared these parameters at week four after injection between the TCA group and the D5W group. Results: NRS values before and 4 weeks after TCA injection (sig 0.001; p <0.05), FSS values (sig 0.020; p <0.05), and SSS values (sig 0.001; p <0.05). NRS before and 4 weeks after injection of D5W (sig 0.002; p <0.05), FSS (sig 0.001; p <0.05), and SSS (sig 0.000; p <0.05). Comparison between TCA injection and D5W injection at 4 weeks after the injection showed that the results was significantly different on NRS (sig 0.806; p> 0.05) for FSS (sig 0.512; p> 0.05) and SSS (sig 0.293; p> 0.05). Conclusion: There is a significant difference in NRS, FSS and SSS values at 4 weeks after hydrodissection injection, using either TCA or D5W. TCA hydrodissection injection compared to D5W hydrodissection injection was equally effective in improving NRS, FSS and SSS after 4 weeks of injection.","PeriodicalId":126692,"journal":{"name":"JPHV (Journal of Pain, Vertigo and Headache)","volume":"297 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121825037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-01DOI: 10.21776/ub.jphv.2022.003.02.4
Auliya Nur Muthmainnina, Shahdevi Nandar Kurniawan
Cerebrovascular disease is the number one cause of epilepsy in the elderly population. Headaches are relatively common in patients with cerebrovascular disorders. The frequency of stroke-related headaches ranges from 7% to 65% with different types of headaches. The prevalence of persistent post-stroke headaches from 7-23%, with follow-up times ranging from 3 months to 3 years after stroke. Persistent headache in the population was associated with high depression and fatigue scores and significantly impacted returning to work. Most headaches at stroke onset will resolve, persistent headaches are a real entity even years after the stroke. The mechanism that might explain the relationship between headache and hemorrhagic stroke is still unclear, including changes in blood vessel walls supported by endothelial dysfunction in migraine sufferers as well as comorbid vascular risk factors such as arterial hypertension or platelet dysfunction. Headache after stroke intracerebral hemorrhage is believed to be the result of vasoconstriction that causes ischemia of the vessel wall.
{"title":"TENSION TYPE HEADACHE (TTH)","authors":"Auliya Nur Muthmainnina, Shahdevi Nandar Kurniawan","doi":"10.21776/ub.jphv.2022.003.02.4","DOIUrl":"https://doi.org/10.21776/ub.jphv.2022.003.02.4","url":null,"abstract":"Cerebrovascular disease is the number one cause of epilepsy in the elderly population. Headaches are relatively common in patients with cerebrovascular disorders. The frequency of stroke-related headaches ranges from 7% to 65% with different types of headaches. The prevalence of persistent post-stroke headaches from 7-23%, with follow-up times ranging from 3 months to 3 years after stroke. Persistent headache in the population was associated with high depression and fatigue scores and significantly impacted returning to work. Most headaches at stroke onset will resolve, persistent headaches are a real entity even years after the stroke. The mechanism that might explain the relationship between headache and hemorrhagic stroke is still unclear, including changes in blood vessel walls supported by endothelial dysfunction in migraine sufferers as well as comorbid vascular risk factors such as arterial hypertension or platelet dysfunction. Headache after stroke intracerebral hemorrhage is believed to be the result of vasoconstriction that causes ischemia of the vessel wall.","PeriodicalId":126692,"journal":{"name":"JPHV (Journal of Pain, Vertigo and Headache)","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129251451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：